Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 20, Iss. 2-3, 2005-08 ,pp. : 120-132

Karger

Access to resources Recommend Favorite

Donepezil for the Treatment of Mild to Moderate Alzheimer’s Disease in France: The Economic Implications

By  

Dementia and Geriatric Cognitive Disorders, Vol. 17, Iss. 1-2, 2003-12 ,pp. : 5-13

Karger

Access to resources Recommend Favorite

Increased Serum Levels of CD95 in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 13, Iss. 3, 2002-03 ,pp. : 178-182

Karger

Access to resources Recommend Favorite

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite

An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial

By  

Dementia and Geriatric Cognitive Disorders, Vol. 15, Iss. 1, 2002-12 ,pp. : 44-54

Karger

Access to resources Recommend Favorite